What is Edgewise Therapeutics, Inc.'s debt issuance costs?

Edgewise Therapeutics, Inc. (EWTX) reported debt issuance costs of $38K in Q1 2025.

What does debt issuance costs mean?

Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.

Dyne Therapeutics, Inc.DYN

$30K—

Scholar RockSRRK

$1.31M—

CRISPR TherapeuticsCRSP

$13.53M—

ModernaMRNA

$5.5M—

Operating income-$54.1M-17.7%

Net income-$49.0M-20.1%

EPS (diluted)-$0.46-7.0%

Cash & equivalents$33.2M-33.5%

Total debt$3.8M-16.8%

Total equity$493.2M+14.8%

Total assets$518.5M+14.1%

Operating cash flow-$42.5M-12.4%

CapEx$260.0K+491%

Free cash flow-$42.8M-12.9%

Market cap$4.18B+61.3%

Return on equity-38.1%+13.4pp

Debt / equity0×0.0×

Current ratio22.6×+1.6×

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Edgewise Therapeutics, Inc.'s debt issuance costs?: Edgewise Therapeutics, Inc. (EWTX) reported debt issuance costs of $38K in Q1 2025.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.